Skip to main content

BIOFIRE® Joint Infection (JI) Panel

1 Test. 39 Targets. ~ 1 Hour.

Mitigate the challenges of diagnosing septic arthritis and prosthetic joint infections with comprehensive results on a menu of 31 causative pathogens and eight antimicrobial resistance markers.


A New Kind of Joint Infection Testing

Joint infections are difficult to diagnose due, in part, to a lack of standardized testing methods and unreliable results from culture.1 Delayed diagnosis is associated with permanent disability and increased mortality (up to 15%).2 The BIOFIRE JI Panel meets these challenges with the syndromic approach, combining 39 targets on one test that produces a single, comprehensive report.

The Power Behind the Panel

The BIOFIRE JI Panel can provide the essential combination of speed, accuracy, and comprehensiveness to enable a fast, definitive identification of a pathogen. 

How the BIOFIRE JI Panel Helps

The BIOFIRE JI Panel enhances joint infection diagnostics by providing reliable results and detecting a range of pathogens and antimicrobial resistance gene targets. Its ability to identify co-detections may contribute to more informed patient management, facilitating quicker and more effective treatment decisions.

Get Reliable Results

The high sensitivity and specificity of the BIOFIRE JI Panel means it has an increased diagnostic yield compared to culture-based methods.4

Test for More Targets

The panel entails one test that identifies multiple pathogens associated with acute joint infections, including Candida spp, Neisseria gonorrhoeae, and Kingella kingae.4

Catch polymicrobial detections

The BIOFIRE JI Panel has been shown to help identify co-detections. Of the 242 positive specimens detected by the BIOFIRE JI Panel, 16 involved co-detections.5

Elevate Patient Management

The BIOFIRE JI Panel may aid in appropriate surgical decision making and reduce time to effective therapy through rapid pathogen identification.4

The Joint Infection Testing Menu

Discover the 39 targets on the BIOFIRE JI Panel, including gram-positive and gram-negative bacteria, yeast, and antimicrobial resistance genes commonly associated with joint infections.

Sample Type
0.2 mL of synovial fluid 

Performance
Overall 91.7% sensitivity and 99.8% specificity3

Syndromic Testing Made Simple

The BIOFIRE® FILMARRAY® Systems run syndromic infectious disease tests. One multiplex assay simultaneously tests for the most common pathogens and antimicrobial resistance genes associated with a particular syndrome.

Learn More About Systems

 

The BIOFIRE® FILMARRAY® TORCH System

The BIOFIRE TORCH System uses multiplex PCR technology to simultaneously test for a comprehensive grouping of targets in about an hour. 

  • Compatible with six-panel syndromic portfolio
  • Reduced footprint provides up to six times the throughput per square foot of laboratory bench space
  • Scalable configuration allows customized throughput
  • Simplified workflow features a touchscreen interface and integrated barcode scanner
  • Data management automation includes LIS connectivity and random-access operation

The BIOFIRE® FILMARRAY® 2.0 System

The BIOFIRE 2.0 System enables simplified test ordering, faster turnaround times, and increased accuracy by minimizing manual data entry.

  • Scalable configuration allows customized throughput and efficient use of laboratory bench space
  • Offers LIS connectivity, random-access operation, and single database management of up to 8 instruments per computer

Service & Support

To order the BIOFIRE JI Panel, contact your regional sales representative or use the following contact information:

Email: salesorders@biofiredx.com

Phone: 1-801-736-6354

US Sales Extension: 1502

International Sales Extension: 1536

Product Information

PRODUCT NAMEPART NUMBERQUANTITY
BIOFIRE JI Panel 30 Pouch KitRFIT-ASY-013830-Pack

1.     Tande JT, Patel R, Clin Microbiol Rev. 2014 Apr; 27(2): 302–345.

2.     Singh JA, Yu S, PLoS One. 2017; 12(8): e0182577.

3.     BIOFIRE® Joint Infection Panel (JI) Instruction Booklet. On file, bioMérieux

4.     Esteban J, et al. Journal of Clinical Microbiology. 25 October, 2023. https://doi.org/10.1128/jcm.00357-23

5.     Graue C, et al. IDWeek 2020; Virtual.